Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells

(2020) Margherita Passariello et al.   Cancers

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

(2020) Man Yee Keung et al.   Journal of Clinical Medicine

Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model

(2020) Barbara Schrörs et al.   Frontiers in Oncology

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

(2019) Ana C. Garrido-Castro et al.   Cancer Discovery

Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model

(2019) Raziye Piranlioglu et al.   Nature Communications

Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer

(2019) Canan Kasikara et al.   CANCER RESEARCH

Recent advances in triple negative breast cancer: the immunotherapy era

(2019) Antonio Marra et al.   BMC Medicine

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

(2019) Javier Cortés et al.   Future Oncology

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy

(2019) Marilina García-Aranda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer

(2019) Wei Xiong Wen et al.   PLoS One

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

(2019) Gloria V. Echeverria et al.   Science Translational Medicine

Current Landscape of Immunotherapy in Breast Cancer

(2019) Sylvia Adams et al.   JAMA Oncology

Advances in Targeted Therapies for Triple-Negative Breast Cancer

(2019) Kelly E. McCann et al.   DRUGS

The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity

(2019) Sangeetha Palakurthi et al.   Cancer Immunology Research

Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer

(2019) Billy Samuel Hill et al.   SEMINARS IN CANCER BIOLOGY

Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion

(2019) Crescenzo D’Alterio et al.   SEMINARS IN CANCER BIOLOGY

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing

(2019) Margherita Passariello et al.   Cancers

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

(2019) Crescenzo D’Alterio et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

(2019) Atsushi Tanaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application

(2019) Adachi et al.   MOLECULES

Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?

(2019) Michelle Bauer et al.   MOLECULES

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling

(2019) Margherita Passariello et al.   Scientific Reports

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

(2019) S. Napolitano et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries

(2019) Biancamaria Cembrola et al.   Biomed Research International

Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications

(2018) Simona Camorani et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells

(2018) Emanuele Sasso et al.   mAbs

Aptamers: Promising Tools for Cancer Diagnosis and Therapy

(2018) Laura Cerchia   Cancers

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

(2018) Chloé Grasselly et al.   Frontiers in Immunology

The clinical promise of immunotherapy in triple-negative breast cancer

(2018) Praveen Vikas et al.   Cancer Management and Research

Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood–Brain Barrier

(2017) Ilaria Monaco et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

(2017) Giovanni Germano et al.   NATURE

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

(2017) Carlos R. Gil Del Alcazar et al.   Cancer Discovery

Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers

(2017) Simona Camorani et al.   Scientific Reports

Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer

(2017) Simona Camorani et al.   Theranostics

Targeting Malignant Brain Tumors with Antibodies

(2017) Rok Razpotnik et al.   Frontiers in Immunology

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

(2017) et al.   Cancers

Practical Approach to Triple-Negative Breast Cancer

(2017) Vijayakrishna K. Gadi et al.   Journal of Oncology Practice

PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway

(2016) Hong Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer

(2016) Elvira D'Ippolito et al.   CANCER RESEARCH

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

(2016) Adrian M. Seifert et al.   CLINICAL CANCER RESEARCH

Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer

(2016) George Plitas et al.   IMMUNITY

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Aptamers as targeted therapeutics: current potential and challenges

(2016) Jiehua Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD

(2016) Eliane Cortez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells

(2015) Simona Camorani et al.   Oncotarget

A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma

(2015) Fengfei Wang et al.   Oncotarget

PDGFRB Promotes Liver Metastasis Formation of Mesenchymal-Like Colorectal Tumor Cells

(2015) Ernst J.A. Steller et al.   NEOPLASIA

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

(2014) Lisa A. Newman et al.   ANNALS OF SURGICAL ONCOLOGY

PDGFR  and   Play Critical Roles in Mediating Foxq1-Driven Breast Cancer Stemness and Chemoresistance

(2014) F. Meng et al.   CANCER RESEARCH

Inhibition of Receptor Signaling and of Glioblastoma-derived Tumor Growth by a Novel PDGFRβ Aptamer

(2014) Simona Camorani et al.   MOLECULAR THERAPY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer

(2013) Giuseppe Curigliano et al.   BREAST

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

(2013) David Akhavan et al.   Cancer Discovery

A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease

(2012) Punit Kaur et al.   BMC CANCER

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity

(2012) Y. Kim et al.   GENES & DEVELOPMENT

PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization, But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer

(2011) J. Liu et al.   CLINICAL CANCER RESEARCH

Aptamers as therapeutics

(2010) Anthony D. Keefe et al.   NATURE REVIEWS DRUG DISCOVERY

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations

(2008) M. Cristofanilli et al.   ANNALS OF ONCOLOGY

Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target

(2008) Sandra D Bohling et al.   MODERN PATHOLOGY